Animal Gastroesophageal Reflux Disease Market Size, Share and Growth Outlook, 2026

Animal Gastroesophageal Reflux Disease Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Animal Gastroesophageal Reflux Disease Market size is forecast to increase from $3.33 Billion in 2026 to $5.89 Billion in 2034 at a CAGR of 7.4% between 2026 and 2034.

The Animal Gastroesophageal Reflux Disease market report provides detailed analysis and outlook of Animal Gastroesophageal Reflux Disease segments including By Product (Treatment Drugs, Diagnostic Tools, Specialized Gastrointestinal Supplements & Veterinary Diets), By Prescription Status (Over-the-Counter, Prescription-Only Medications ), By Animal Type (Companion Animals, Livestock Animals ), By Route of Administration (Oral, Injectable ), By Distribution Channel (Veterinary Hospitals & Specialty Clinics, E-Commerce Platforms & Online Pet Pharmacies, Retail Pharmacies & Pet Specialty Stores) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Animal Gastroesophageal Reflux Disease (GERD) Industry Overview

Expanding Access to Veterinary Acid Suppression Therapies

The animal gastroesophageal reflux disease (GERD) industry is evolving through regulatory initiatives that improve access to proven acid-suppression treatments for livestock and companion animals. A significant development is Health Canada's administrative consultation regarding modifications to the Prescription Drug List for veterinary products containing omeprazole and its magnesium salts. Omeprazole remains one of the most widely utilized proton-pump inhibitors (PPIs) in veterinary medicine due to its effectiveness in reducing gastric acid secretion and managing gastroesophageal reflux disease, gastric ulceration, and erosive gastrointestinal disorders across multiple mammalian species. The proposed regulatory amendment would reclassify specific veterinary formulations as non-prescription products when used for the treatment or prevention of gastric ulcers and acid reflux symptoms in horses at maintenance dosages below 2 mg/kg/day. This regulatory shift is expected to increase accessibility for agricultural operators while supporting broader adoption of preventive gastrointestinal health management strategies in equine care.

Growing Focus on Preventive Gastrointestinal Management

Preventive treatment protocols are becoming increasingly important within the veterinary GERD landscape as clinicians seek to minimize complications associated with severe gastrointestinal disorders. Veterinary healthcare providers are placing greater emphasis on early intervention strategies that reduce acid-related tissue damage and improve long-term digestive health outcomes. The wider availability of proton-pump inhibitors and other acid-reducing therapies is supporting proactive management of gastric ulcer syndromes, acid reflux conditions, and stress-related gastrointestinal disorders in performance animals and livestock populations. As awareness of digestive health continues to grow, preventive treatment approaches are becoming a key component of veterinary gastroenterology and animal welfare programs.

Standardization of GERD Prevention in Oncology Care

The industry is also benefiting from increased standardization of gastrointestinal protection protocols during intensive veterinary treatments. The U.S. FDA Center for Veterinary Medicine issued updated safety labeling requirements for Stelfonta (tigilanol tiglate injection), a treatment used in canine mast cell tumor management. Rapid tumor destruction following treatment can trigger extensive histamine release, potentially causing severe gastric hyperacidity, gastric ulceration, and gastroesophageal reflux disease. To address these risks, veterinarians are now required to implement a structured preventive gastrointestinal regimen that includes both H1 receptor blockers and H2 receptor-blocking therapies such as famotidine administered at 0.5 mg/kg every 12 hours for eight consecutive days. These requirements reinforce the growing role of standardized GERD prevention protocols within veterinary oncology and highlight the increasing integration of gastrointestinal safety management into advanced animal healthcare practices.

Animal Gastroesophageal Reflux Disease Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Animal Gastroesophageal Reflux Disease market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc., Virbac, Elanco Animal Health Incorporated, Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bayer AG, Mars, Inc. (Antech/VCA Diagnostics), IDEXX Laboratories, Inc.. The Animal Gastroesophageal Reflux Disease market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Animal Gastroesophageal Reflux Disease industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Animal Gastroesophageal Reflux Disease Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Animal Gastroesophageal Reflux Disease companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Animal Gastroesophageal Reflux Disease markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Animal Gastroesophageal Reflux Disease Market Competitive Benchmarking and Company Analysis

Leading companies in Animal Gastroesophageal Reflux Disease industry include- Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc., Virbac, Elanco Animal Health Incorporated, Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bayer AG, Mars, Inc. (Antech/VCA Diagnostics), IDEXX Laboratories, Inc.. The Animal Gastroesophageal Reflux Disease market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Animal Gastroesophageal Reflux Disease Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Animal Gastroesophageal Reflux Disease market remains one of the strongest-performing segments in the country.
The US Animal Gastroesophageal Reflux Disease Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Animal Gastroesophageal Reflux Disease market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Animal Gastroesophageal Reflux Disease industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Animal Gastroesophageal Reflux Disease markets

Canada's strong Animal Gastroesophageal Reflux Disease sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Animal Gastroesophageal Reflux Disease market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Animal Gastroesophageal Reflux Disease Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Animal Gastroesophageal Reflux Disease market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Animal Gastroesophageal Reflux Disease population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Animal Gastroesophageal Reflux Disease industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Animal Gastroesophageal Reflux Disease market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Animal Gastroesophageal Reflux Disease sales through 2034

France Animal Gastroesophageal Reflux Disease companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Animal Gastroesophageal Reflux Disease Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Animal Gastroesophageal Reflux Disease distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Animal Gastroesophageal Reflux Disease Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Animal Gastroesophageal Reflux Disease market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Animal Gastroesophageal Reflux Disease industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Animal Gastroesophageal Reflux Disease industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Animal Gastroesophageal Reflux Disease Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Animal Gastroesophageal Reflux Disease market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Animal Gastroesophageal Reflux Disease market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Animal Gastroesophageal Reflux Disease Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Animal Gastroesophageal Reflux Disease Market Segmentation

By Product
Treatment Drugs
Diagnostic Tools
Specialized Gastrointestinal Supplements & Veterinary Diets
By Prescription Status
Over-the-Counter
Prescription-Only Medications
By Animal Type
Companion Animals
Livestock Animals
By Route of Administration
Oral
Injectable
By Distribution Channel
Veterinary Hospitals & Specialty Clinics
E-Commerce Platforms & Online Pet Pharmacies
Retail Pharmacies & Pet Specialty Stores

Top Companies in Animal Gastroesophageal Reflux Disease Industry

Zoetis Inc.
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
Virbac
Elanco Animal Health Incorporated
Dechra Pharmaceuticals PLC
Vetoquinol S.A.
Bayer AG
Mars, Inc. (Antech/VCA Diagnostics)
IDEXX Laboratories, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025